191 related articles for article (PubMed ID: 29032266)
41. Comparable antileukemia/lymphoma effects in nonremission patients undergoing allogeneic hematopoietic cell transplantation with a conventional cytoreductive or reduced-intensity regimen.
Maruyama D; Fukuda T; Kato R; Yamasaki S; Usui E; Morita-Hoshi Y; Kim SW; Mori S; Heike Y; Makimoto A; Tajima K; Tanosaki R; Tobinai K; Takaue Y
Biol Blood Marrow Transplant; 2007 Aug; 13(8):932-41. PubMed ID: 17640597
[TBL] [Abstract][Full Text] [Related]
42. Body Weight Loss Before Allogeneic Hematopoietic Stem Cell Transplantation Predicts Survival Outcomes in Acute Leukemia Patients.
Tamaki M; Nakasone H; Nakamura Y; Kawamura M; Kawamura S; Takeshita J; Yoshino N; Misaki Y; Yoshimura K; Matsumi S; Gomyo A; Tanihara A; Kusuda M; Kameda K; Akahoshi Y; Kimura SI; Kako S; Kanda Y
Transplant Cell Ther; 2021 Apr; 27(4):340.e1-340.e6. PubMed ID: 33836885
[TBL] [Abstract][Full Text] [Related]
43. Changes in incidence and causes of non-relapse mortality after allogeneic hematopoietic cell transplantation in patients with acute leukemia/myelodysplastic syndrome: an analysis of the Japan Transplant Outcome Registry.
Kurosawa S; Yakushijin K; Yamaguchi T; Atsuta Y; Nagamura-Inoue T; Akiyama H; Taniguchi S; Miyamura K; Takahashi S; Eto T; Ogawa H; Kurokawa M; Tanaka J; Kawa K; Kato K; Suzuki R; Morishima Y; Sakamaki H; Fukuda T
Bone Marrow Transplant; 2013 Apr; 48(4):529-36. PubMed ID: 22964595
[TBL] [Abstract][Full Text] [Related]
44. Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease.
Devillier R; Fürst S; El-Cheikh J; Castagna L; Harbi S; Granata A; Crocchiolo R; Oudin C; Mohty B; Bouabdallah R; Chabannon C; Stoppa AM; Charbonnier A; Broussais-Guillaumot F; Calmels B; Lemarie C; Rey J; Vey N; Blaise D
Biol Blood Marrow Transplant; 2014 Mar; 20(3):370-4. PubMed ID: 24315846
[TBL] [Abstract][Full Text] [Related]
45. Prognostic pre-transplant factors in myelodysplastic syndromes primarily treated by high dose allogeneic hematopoietic stem cell transplantation: a retrospective study of the MDS subcommittee of the CMWP of the EBMT.
Cremers EM; van Biezen A; de Wreede LC; Scholten M; Vitek A; Finke J; Platzbecker U; Beelen D; Schwerdtfeger R; Volin L; Harhalakis N; Blijlevens N; Nagler A; Kröger N; de Witte T
Ann Hematol; 2016 Dec; 95(12):1971-1978. PubMed ID: 27650829
[TBL] [Abstract][Full Text] [Related]
46. Role of HCT-comorbidity index, age and disease status at transplantation in predicting survival and non-relapse mortality in patients with myelodysplasia and leukemia undergoing reduced-intensity-conditioning hemopoeitic progenitor cell transplantation.
Bokhari SW; Watson L; Nagra S; Cook M; Byrne JL; Craddock C; Russell NH
Bone Marrow Transplant; 2012 Apr; 47(4):528-34. PubMed ID: 21743502
[TBL] [Abstract][Full Text] [Related]
47. Comparison of Intensive Chemotherapy and Hypomethylating Agents before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A Study of the Myelodysplastic Syndrome Subcommittee of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplant Research.
Potter VT; Iacobelli S; van Biezen A; Maertens J; Bourhis JH; Passweg JR; Yakhoub-Agha I; Tabrizi R; Bay JO; Chevallier P; Chalandon Y; Huynh A; Cahn JY; Ljungman P; Craddock C; Lenhoff S; Russell NH; Fegueux N; Socié G; Bruno B; Meijer E; Mufti GJ; de Witte T; Robin M; Kröger N
Biol Blood Marrow Transplant; 2016 Sep; 22(9):1615-1620. PubMed ID: 27264633
[TBL] [Abstract][Full Text] [Related]
48. Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis.
Murthy HS; Zhang MJ; Chen K; Ahmed S; Deotare U; Ganguly S; Kansagra A; Michelis FV; Nishihori T; Patnaik M; Abid MB; Aljurf M; Arai Y; Bacher U; Badar T; Badawy SM; Ballen K; Battiwalla M; Beitinjaneh A; Bejanyan N; Bhatt VR; Brown VI; Martino R; Cahn JY; Castillo P; Cerny J; Chhabra S; Copelan E; Daly A; Dholaria B; Diaz Perez MA; Freytes CO; Grunwald MR; Hashmi S; Hildebrandt GC; Jamy O; Joseph J; Kanakry CG; Khera N; Krem MM; Kuwatsuka Y; Lazarus HM; Lekakis LJ; Liu H; Modi D; Munshi PN; Mussetti A; Palmisiano N; Patel SS; Rizzieri DA; Seo S; Shah MV; Sharma A; Sohl M; Solomon SR; Ulrickson M; Ustun C; van der Poel M; Verdonck LF; Wagner JL; Wang T; Wirk B; Zeidan A; Litzow M; Kebriaei P; Hourigan CS; Weisdorf DJ; Saber W; Kharfan-Dabaja MA
Blood Adv; 2023 Nov; 7(22):7007-7016. PubMed ID: 37792849
[TBL] [Abstract][Full Text] [Related]
49. Differential prognostic impact of pretransplant comorbidity on transplant outcomes by disease status and time from transplant: a single Japanese transplant centre study.
Kataoka K; Nannya Y; Ueda K; Kumano K; Takahashi T; Kurokawa M
Bone Marrow Transplant; 2010 Mar; 45(3):513-20. PubMed ID: 19684632
[TBL] [Abstract][Full Text] [Related]
50. Factors Predicting Graft-versus-Host Disease-Free, Relapse-Free Survival after Allogeneic Hematopoietic Cell Transplantation: Multivariable Analysis from a Single Center.
Solh M; Zhang X; Connor K; Brown S; Solomon SR; Morris LE; Holland HK; Bashey A
Biol Blood Marrow Transplant; 2016 Aug; 22(8):1403-1409. PubMed ID: 27095692
[TBL] [Abstract][Full Text] [Related]
51. Impact of pre-transplant depression on outcomes of allogeneic and autologous hematopoietic stem cell transplantation.
El-Jawahri A; Chen YB; Brazauskas R; He N; Lee SJ; Knight JM; Majhail N; Buchbinder D; Schears RM; Wirk BM; Wood WA; Ahmed I; Aljurf M; Szer J; Beattie SM; Battiwalla M; Dandoy C; Diaz MA; D'Souza A; Freytes CO; Gajewski J; Gergis U; Hashmi SK; Jakubowski A; Kamble RT; Kindwall-Keller T; Lazarus HM; Malone AK; Marks DI; Meehan K; Savani BN; Olsson RF; Rizzieri D; Steinberg A; Speckhart D; Szwajcer D; Schoemans H; Seo S; Ustun C; Atsuta Y; Dalal J; Sales-Bonfim C; Khera N; Hahn T; Saber W
Cancer; 2017 May; 123(10):1828-1838. PubMed ID: 28102896
[TBL] [Abstract][Full Text] [Related]
52. Outcome of 93 patients with relapse or progression following allogeneic hematopoietic cell transplantation.
Kurosawa S; Fukuda T; Tajima K; Saito B; Fuji S; Yokoyama H; Kim SW; Mori S; Tanosaki R; Heike Y; Takaue Y
Am J Hematol; 2009 Dec; 84(12):815-20. PubMed ID: 19899134
[TBL] [Abstract][Full Text] [Related]
53. Pulmonary Impairment after Respiratory Viral Infections Is Associated with High Mortality in Allogeneic Hematopoietic Cell Transplant Recipients.
Sheshadri A; Chemaly RF; Alousi AM; Shah PK; Rondon G; Bashoura L; Kmeid J; Azzi J; Blanco DW; Kaous M; Dickey BF; Champlin RE; Shah DP
Biol Blood Marrow Transplant; 2019 Apr; 25(4):800-809. PubMed ID: 30521974
[TBL] [Abstract][Full Text] [Related]
54. Does the hematopoietic cell transplantation specific comorbidity index predict transplant outcomes? A validation study in a large cohort of umbilical cord blood and matched related donor transplants.
Majhail NS; Brunstein CG; McAvoy S; DeFor TE; Al-Hazzouri A; Setubal D; Arora M; Le CT; Wagner JE; Weisdorf DJ
Biol Blood Marrow Transplant; 2008 Sep; 14(9):985-992. PubMed ID: 18721761
[TBL] [Abstract][Full Text] [Related]
55. Level of vascular endothelial growth factor predicts both relapse and nonrelapse mortality after allogeneic hematopoietic stem cell transplantation.
Moiseev IS; Lapin SV; Surkova EA; Lerner MY; Vavilov VN; Afanasyev BV
Biol Blood Marrow Transplant; 2013 Dec; 19(12):1677-82. PubMed ID: 24035780
[TBL] [Abstract][Full Text] [Related]
56. Prognostic Factors for Mortality among Day +100 Survivors after Allogeneic Hematopoietic Cell Transplantation.
Patel SS; Rybicki LA; Corrigan D; Bolwell B; Dean R; Liu H; Gerds AT; Hanna R; Hill B; Jagadeesh D; Kalaycio M; Pohlman B; Sobecks R; Majhail NS; Hamilton BK
Biol Blood Marrow Transplant; 2018 May; 24(5):1029-1034. PubMed ID: 29369800
[TBL] [Abstract][Full Text] [Related]
57. The hematopoietic cell transplantation-specific comorbidity index fails to predict outcomes in high-risk AML patients undergoing allogeneic transplantation--investigation of potential limitations of the index.
Birninger N; Bornhäuser M; Schaich M; Ehninger G; Schetelig J
Biol Blood Marrow Transplant; 2011 Dec; 17(12):1822-32. PubMed ID: 21708108
[TBL] [Abstract][Full Text] [Related]
58. Predictive implications of albumin and C-reactive protein for progression to pneumonia and poor prognosis in Stenotrophomonas maltophilia bacteremia following allogeneic hematopoietic stem cell transplantation.
Harada K; Sekiya N; Konishi T; Nagata A; Yamada Y; Takezaki T; Kaito S; Kurosawa S; Sakaguchi M; Yasuda S; Sasaki S; Yoshioka K; Watakabe-Inamoto K; Igarashi A; Najima Y; Hagino T; Muto H; Kobayashi T; Doki N; Kakihana K; Sakamaki H; Ohashi K
BMC Infect Dis; 2017 Sep; 17(1):638. PubMed ID: 28938875
[TBL] [Abstract][Full Text] [Related]
59. Risk Assessment in Adult T Cell Leukemia/Lymphoma Treated with Allogeneic Hematopoietic Stem Cell Transplantation.
Yoshimitsu M; Tanosaki R; Kato K; Ishida T; Choi I; Takatsuka Y; Fukuda T; Eto T; Hidaka M; Uchida N; Miyamoto T; Nakashima Y; Moriuchi Y; Nagafuji K; Miyazaki Y; Ichinohe T; Takanashi M; Atsuta Y; Utsunomiya A;
Biol Blood Marrow Transplant; 2018 Apr; 24(4):832-839. PubMed ID: 29155320
[TBL] [Abstract][Full Text] [Related]
60. Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index in Nonmyeloablative Allogeneic Stem Cell Transplantation.
Veeraputhiran M; Yang L; Sundaram V; Arai S; Lowsky R; Miklos D; Meyer E; Muffly L; Negrin R; Rezvani A; Shizuru J; Weng WK; Johnston L
Biol Blood Marrow Transplant; 2017 Oct; 23(10):1744-1748. PubMed ID: 28668491
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
